HC Wainwright Reiterates Overweight Rating for Indaptus Therapeutics (NASDAQ:INDP)

Indaptus Therapeutics (NASDAQ:INDP – Get Rating)‘s stock had its “overweight” rating reiterated by analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $15.00 price objective on the stock.

Indaptus Therapeutics Price Performance

Shares of NASDAQ INDP opened at $1.61 on Wednesday. Indaptus Therapeutics has a 1 year low of $1.25 and a 1 year high of $4.25. The firm has a 50-day simple moving average of $1.67 and a two-hundred day simple moving average of $1.91.

Hedge Funds Weigh In On Indaptus Therapeutics

A number of institutional investors have recently modified their holdings of INDP. Northern Trust Corp purchased a new position in shares of Indaptus Therapeutics during the first quarter worth approximately $41,000. Renaissance Technologies LLC acquired a new stake in shares of Indaptus Therapeutics during the second quarter worth $51,000. State Street Corp acquired a new stake in shares of Indaptus Therapeutics during the first quarter worth $78,000. Strategy Asset Managers LLC acquired a new position in Indaptus Therapeutics during the third quarter valued at $120,000. Finally, Vanguard Group Inc. lifted its position in Indaptus Therapeutics by 18.7% during the first quarter. Vanguard Group Inc. now owns 242,235 shares of the company’s stock valued at $969,000 after purchasing an additional 38,216 shares during the period. 6.87% of the stock is owned by hedge funds and other institutional investors.

About Indaptus Therapeutics

(Get Rating)

Indaptus Therapeutics, Inc is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria.